PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Videos|November 16, 2022
Captisol- Why it’s the UNRIVALED Modified Cyclodextrin
Author(s)Ligand
Key Learning Objectives
- Captisol is in over a dozen FDA approved products with multiple product approvals coming in the next year. These approvals include oral and ophthalmic routes of administration. Proven safe!
- A team of experts with 20+ years of experience who are ready to answer any questions are what sets Captisol apart from other modified cyclodextrins.
- Ligand formulation services are now available to assist with consideration of CAPTISOL for solving product development issues and achieving Target Product Profile goals
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.